10 months ago
Natco Pharma Launches Generic Everolimus Tablets in US
Natco Pharma, an Indian company, has released a new medicine called Everolimus tablets in the United States.
This medicine is like a "generic" version of a drug originally made by Novartis, called Zortress.
It's a special kind of medicine that helps stop a person's body from rejecting a new organ, like a kidney or liver, after a transplant.
Natco's partner in the US, Breckenridge Pharmaceutical, will sell it.
This means people who have had transplants might have a more affordable option for this important medication.
The tablets come in different strengths and have been available in various forms since 2021.
Natco Pharma has launched generic Everolimus tablets in the US market.
The drug is an immunosuppressant used to prevent organ rejection after kidney and liver transplants.
Natco's US subsidiary, Breckenridge Pharmaceutical, will market the product.
Everolimus tablets are a generic version of Novartis's Zortress.
The drug is available in 0.25mg, 0.5mg, and 0.75mg strengths.
- Who
- Natco Pharma and its marketing partner Breckenridge Pharmaceutical
- What
- Launched generic Everolimus tablets
- Where
- US market
- When
- October 31, 2025
- Why
- To provide a generic option for immunosuppression post-transplant
Key facts
- Manufacturer
- Natco Pharma
- Drug Name
- Everolimus Tablets
- Generic of
- Zortress by Novartis
- Therapeutic Class
- Immunosuppressant
- Indication
- Prophylaxis of organ rejection in kidney and liver transplant patients
- Marketing Partner
- Breckenridge Pharmaceutical
Quotes
Natco Pharma
The Hyderabad-based company that launched Everolimus tablets.
“Natco’s marketing partner for the Abbreviated New Drug Application (ANDA), Breckenridge Pharmaceutical, the US subsidiary of Towa International, plans to launch the product immediately in the US market.”
thehindubusinessline.com
Sources
Related news
Natco Pharma Expands Beyond Generics Amid Intensifying Competition
Natco Pharma Invests Over Rs 130 Crore in eGenesis
Indian Stocks Set for Cautious Start Amid Global Risks
Indian stocks in focus after orders, approvals and regulatory updates
Stocks in News: IPO Debuts, Stake Sales, and Corporate Updates
